To elucidate the role of JAK-3 phosphorylation, we examined the effects of JAK-3 inhibition in cytokine-stimulated rheumatoid synovial fibroblasts in vitro. OSM has been shown to activate synoviocytes to produce proinflammatory mediators, and JAK-3 phosphorylation has been demonstrated in OSM-stimulated Veliparib synovial fibroblasts [18]. CP-690,550 is a potent inhibitor of JAK-3, while ICNB028050 is a selective JAK1/2 inhibitor. We therefore examined the effects of JAK-3 inhibition on OSM-induced synovial fibroblasts by comparing their differential effects on JAK/STAT signalling. We stimulated

synovial fibroblasts with OSM to activate JAK1/2/3. OSM stimulation also induced STAT-1/-3/-5 phosphorylation in synovial fibroblasts. CP-690,550 blocked OSM-induced JAK-1/-2/-3 and STAT-1/-3/-5 phosphorylation. Unexpectedly, INCB028050 also inhibited JAK-3 in addition to JAK-1/-2 (Fig. 2). These findings demonstrate that mTOR inhibitor CP-690,550 and INCB028050 had similar potencies in terms of suppressing JAK-3, as well as JAK-1/-2 and downstream STAT-1/-3/-5. We assessed the role of JAK-3 in the biological functions of rheumatoid synovial fibroblasts using the JAK-3-specific inhibitor PF-956980 [19]. To evaluate the selectivity of JAK family inhibition, we compared the effects of PF-956980

with CP-690,550 and INCB028050 in OSM-stimulated synovial fibroblasts. As shown in Fig. 3, PF-956980 efficiently blocked OSM-induced JAK-3 phosphorylation,

but had no effect on OSM-induced JAK-1 or JAK-2 phosphorylation in synovial fibroblasts. In contrast, CP-690,550 and INCB028050 blocked JAK-1/-2/-3 phosphorylation in OSM-stimulated synovial fibroblasts. We further examined the effect of JAK-3 inhibition on downstream STATs activation. Selective JAK-3 inhibition caused by PF-956980 prevented OSM-induced STAT-1/-5 activation, but had no effect on OSM-induced STAT-3 activation. In contrast, CP-690,550 and INCB028050 pretreatments blocked activation of all STAT members (STAT-1, -3 and -5) in synovial fibroblasts (Fig. 3). These results suggest that pharmacological JAK-1/-2 inhibition specifically blocks downstream STAT-3 activation, which is involved in the proinflammatory pathway. OSM induces gene expression Lonafarnib ic50 of cytokines/chemokines or acute phase serum amyloid A (SAA) [20, 21]. To gain insights into the mechanism of OSM signalling leading to induction of MCP-I and acute-phase SAA1/2 gene expression, we extracted total RNA from synovial fibroblasts after treatment with OSM or OSM plus JAK inhibitors for 6 h and subjected it to PCR analysis. As shown in Fig. 4a, PF-956980, CP-690,550 and INCB028050 suppressed OSM-induced MCP-I gene expression. However, although CP-690,550 and INCB028050 also completely blocked OSM-induced SAA1/2 mRNA induction, PF-982560 failed to suppress this induction (Fig. 4b).